AACHEN, Germany--(BUSINESS WIRE)--PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a ...
Site provides the world’s largest HPL output with 20,000L annual capacity and a dual-source GMP strategy for secure, resilient supply from Aachen AACHEN, Germany, July 31, 2025 (GLOBE NEWSWIRE) -- PL ...
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has issued a Material Qualification Certificate for ELAREM™ Ultimate-FD PLUS (GMP Grade) cell culture media. The PMDA Certification is the ...
AACHEN, Germany, Oct. 28, 2025 (GLOBE NEWSWIRE) -- PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion ...
Summit Pharmaceuticals International Corp. to serve as exclusive distributor for cell culture supplements in Japanese Market. The agreement marks PL BioScience’s first exclusive distribution ...
Worldwide first artificial Human Platelet Lysate (HPL) solution – a key ingredient for the research & production of cell-based pharmaceuticals – developed based on artificial platelet technology from ...
The companies agree to a worldwide Human Platelet Lysate (HPL) Patent License and Assignment Agreement, including redirection of HPL customers from Macopharma to PL BioScience. AACHEN, ...
New 1,200 m² facility in Aachen expands headquarters to support company growth and scale Human Platelet Lysate productionSite provides the world’s largest HPL output with 20,000L annual capacity and a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results